In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia

International Journal of Antimicrobial Agents

Volumn 32, Issue 6, 2008, Pages 494-498

  Croisier, Delphine ^a,b   Martha, Benoit ^a,b   Piroth, Lionel ^a,b   Chavanet, Pascal ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b IFR Sante STIC   (France)

Author keywords

Ceftazidime; Continuous infusion; Pharmacodynamics; Pseudomonas infection; Tobramycin

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EXPERIMENTAL MODEL; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; COLONY COUNT, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; RABBITS; SPLEEN; TOBRAMYCIN;

EID: 55249125648     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.010     Document Type: Article

References (58)

1. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11 (2005) 68-74
2. Vidal F., Mensa J., Almela M., Martinez J.A., Marco F., Casals C., et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156 (1996) 2121-2126
3. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5 (2005) 581-589
4. Roberts J.A., Paratz J., Paratz E., Krueger W.A., and Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30 (2007) 11-18
5. Mouton J.W., and Vinks A.A. Continuous infusion of beta-lactams. Curr Opin Crit Care 13 (2007) 598-606
6. Döring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Hoiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
7. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 365 (2005) 573-578
8. Masterton R.G., Galloway A., French G., Street M., Armstrong J., Brown E., et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62 (2008) 5-34
9. Rahme L.G., Stevens E.J., Wolfort S.F., Shao J., Tompkins R.G., and Ausubel F.M. Common virulence factors for bacterial pathogenicity in plants and animals. Science 268 (1995) 1899-1902
10. Comité de l'Antibiogramme de la Société Française de Microbiologie. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Technical recommendations for in vitro susceptibility testing. Clin Microbiol Infect 1996;251:11-25.
11. Piroth L., Martin L., Coulon A., Lequeu C., Duong M., Buisson M., et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 43 (1999) 2484-2492
12. Croisier D., Chavanet P., Lequeu C., Ahanou A., Nierlich A., Neuwirth C., et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with varying susceptibilities to fluoroquinolones. J Antimicrob Chemother 50 (2002) 349-360
13. Drusano G.L., Joshi J., Forrest A., Ruxer R., Standiford H., Leslie J., et al. Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother 27 (1985) 605-607
14. LeBel M., Barbeau G., Vallee F., and Bergeron M.G. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother 28 (1985) 713-715
15. Ljungberg B., and Nilsson-Ehle I. Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients. Eur J Clin Pharmacol 34 (1988) 173-178
16. Warns H., Lode H., Harnoss C.M., Kemmerich B., Koeppe P., and Wagner J. Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother 12 Suppl. A (1983) 235-240
17. Naber K.G., Kees F., and Grobecker H. Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections. J Antimicrob Chemother 12 Suppl. A (1983) 41-45
18. Leroy A., Leguy F., Borsa F., Spencer G.R., Fillastre J.P., and Humbert G. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother 25 (1984) 638-642
19. Mouton J.W., Vinks A.A., and Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41 (1997) 733-738
20. Cousson J., Floch T., Vernet-Garnier V., Appriou M., Petit J.S., Jovenin N., et al. Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia. Pathol Biol (Paris) 53 (2005) 546-550
21. Beringer P.M., Vinks A.A.T.M.M., Jelliffe R.W., and Shapiro B.J. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 44 (2000) 809-813
22. Martha B., Croisier D., Durand D., Hocquet D., Plesiat P., Piroth L., et al. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin. Clin Microbiol Infect 12 (2006) 426-432
23. Fetzer A.E., Werner A.S., and Hagstrom J.W. Pathologic features of pseudomonal pneumonia. Am Rev Respir Dis 96 (1967) 1121-1130
24. Noone P., and Rogers B.T. Pneumonia caused by coliforms and Pseudomonas aeruginosa. J Clin Pathol 29 (1976) 652-656
25. Potts S.B., Roggli V.L., and Spock A. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatr Pathol Lab Med 15 (1995) 707-721
26. Rose H.D., Heckman M.G., and Unger J.D. Pseudomonas aeruginosa pneumonia in adults. Am Rev Respir Dis 107 (1973) 416-422
27. Burns J.L., Van Dalfsen J.M., Shawar R.M., Otto K.L., Garber R.L., Quan J.M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Antimicrob Chemother 179 (1999) 1190-1196
28. Lynch III J.P. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119 2 Suppl (2001) 373S-384S
29. Crouch Brewer S., Wunderink R.G., Jones C.B., and Leeper K.V. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109 (1996) 1019-1029
30. Garau J., and Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis 16 (2003) 135-143
31. Rello J., Bodi M., Mariscal D., Navarro M., Diaz E., Gallego M., et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 123 (2003) 174-180
32. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
33. Drusano G.L. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45 Suppl. 1 (2007) S89-S95
34. Gordin F.M., Rusnak M.G., and Sande M.A. Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia. Antimicrob Agents Chemother 31 (1987) 398-403
35. Cappelletty D.M., Kang S.L., Palmer S.M., and Rybak M.J. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 39 (1995) 1797-1801
36. den Hollander J.G., Fuursted K., Verbrugh H.A., and Mouton J.W. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 42 (1998) 749-754
37. Mouton J.W., van Ogtrop M.L., Andes D., and Craig W.A. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 43 (1999) 2473-2478
38. Girardi C., Tonnellier M., Goldstein I., Sartorius A., Wallet F., and Rouby J.J. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia. Intensive Care Med 32 (2006) 2042-2048
39. McColm A.A., and Ryan D.M. Penetration of ceftazidime into the rabbit respiratory tract. J Antimicrob Chemother 18 (1986) 593-597
40. Eisenberg E.J., Conzentino P., Eickhoff W.M., and Cundy K.C. Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J Pharmacol Toxicol Methods 29 (1993) 93-98
41. Valcke Y., Pauwels R., and Van der Straeten M. The penetration of aminoglycosides into the alveolar lining fluid of rats. The effect of airway inflammation. Am Rev Respir Dis 142 (1990) 1099-1103
42. Boselli E., Breilh D., Rimmele T., Poupelin J.C., Saux M.C., Chassard D., et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med (2004)
43. Boselli E., Breilh D., Djabarouti S., Guillaume C., Rimmele T., Gordien J.B., et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med 33 (2007) 1519-1523
44. Braude A.C., Hornstein A., Klein M., Vas S., and Rebuck A.S. Pulmonary disposition of tobramycin. Am Rev Respir Dis 127 (1983) 563-565
45. Carcas A.J., Garcia-Satue J.L., Zapater P., and Frias-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 65 (1999) 245-250
46. Mazzei T., Novelli A., De Lalla F., Mini E., and Periti P. Tissue penetration and pulmonary disposition of tobramycin. J Chemother 7 (1995) 363-370
47. Pennington J.E., and Stone R.M. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis 140 (1979) 881-889
48. Rello J., Mariscal D., March F., Jubert P., Sanchez F., Valles J., et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?. Am J Respir Crit Care Med 157 (1998) 912-916
49. Reinhardt A., Kohler T., Wood P., Rohner P., Dumas J.L., Ricou B., et al. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 51 (2007) 1341-1350
50. Fish D.N., Piscitelli S.C., and Danziger L.H. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15 (1995) 279-291
51. Hocquet D., Berthelot P., Roussel-Delvallez M., Favre R., Jeannot K., Bajolet O., et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 51 (2007) 3531-3536
52. Henrichfreise B., Wiegand I., Luhmer-Becker I., and Wiedemann B. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother 51 (2007) 3642-3649
53. Henrichfreise B., Wiegand I., Pfister W., and Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa from Germany and correlation with hypermutation. Antimicrob Agents Chemother (2007)
54. Lodise T.P., Miller C.D., Graves J., Furuno J.P., McGregor J.C., Lomaestro B., et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 51 (2007) 417-422
55. Kang C.-I., Kim S.-H., Kim H.-B., Park S.-W., Choe Y.-J., Oh M.-D., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37 (2003) 745-751
56. Lodise Jr. T.P., Patel N., Kwa A., Graves J., Furuno J.P., Graffunder E., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51 (2007) 3510-3515
57. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., and Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005) 1306-1311
58. Robaux M.A., Dube L., Caillon J., Bugnon D., Kergueris M.F., Navas D., et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother 47 (2001) 617-622